Search

Displaying results 1561 - 1570 of 3020 in total
  1. Drug

    Ginkgo biloba leaf oil

    go.drugbank.com/drugs/DB14285
    Investigational

    Ginkgo biloba leaf oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Panax ginseng root oil

    go.drugbank.com/drugs/DB14286
    Investigational

    Panax ginseng root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Garcinia gummi-gutta fruit

    go.drugbank.com/drugs/DB14365
    Investigational

    Garcinia gummi-gutta fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells.

    Categories: Prostaglandins E
  5. Drug

    Formaldehyde

    go.drugbank.com/drugs/DB03843
    ApprovedVet approved

    (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717)

  6. Drug

    Icaridin

    go.drugbank.com/drugs/DB14074
    Investigational

    Icaridin, also known as Picaridin or hydroxy-ethyl isobutyl piperidine carboxylate, is a cyclic amine and a member of the piperidine chemical family. Piperidines are structural components of piperine, which is a plant extract from the ge...

  7. Drug

    Mephentermine

    go.drugbank.com/drugs/DB01365
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)

  8. Drug

    HZT-501

    go.drugbank.com/drugs/DB05369
    Investigational

    HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.

  9. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826] … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.

  10. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug … It was developed by Novartis and was granted FDA approval on November 15, 2019.